Remifentanil Hydrochloride Injection — FDA Drug Shortage

Current — Hikma Pharmaceuticals USA, Inc.

The FDA lists a drug shortage record for Remifentanil Hydrochloride Injection (injection) from Hikma Pharmaceuticals USA, Inc. with status Current. The shortage was first posted on Jun 28, 2022. Reported reason: Demand increase for the drug

Shortage details

Status
Current
Company
Hikma Pharmaceuticals USA, Inc.
Package NDC
0143-9393-10
Dosage Form
Injection
Presentation
Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)
Initial Posting
Jun 28, 2022

Reason

Demand increase for the drug

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.